Intravesical gemcitabine and docetaxel vs. re‐induction Bacillus Calmette Guerin as first‐line salvage therapy for non‐muscle invasive bladder cancer

Abstract Objectives To compare the outcomes between re‐induction Bacillus Calmette‐Guérin (BCG) and sequential intravesical gemcitabine‐docetaxel (Gem/Doce) therapy in patients with high‐grade (HG) non‐muscle invasive bladder cancer (NMIBC) following failure of initial induction BCG. Materials and m...

Full description

Bibliographic Details
Published in:BJUI Compass
Main Authors: Kylie Yen‐Yi Lim, Tran Ngoc An Huynh, Gavin Wei, Jincy Kuriakose, Obaidullah Fazli, David Pook, Sarah Ransley, Janice Downie, Scott Donnellan, Weranja Ranasinghe
Format: Article
Language:English
Published: Wiley 2025-04-01
Subjects:
BCG failure
gemcitabine‐docetaxel
non‐muscle invasive bladder cancer
salvage therapy
Online Access:https://doi.org/10.1002/bco2.70012

Internet

https://doi.org/10.1002/bco2.70012

Similar Items